Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на этот ресурс:
http://elib.usma.ru/handle/usma/4883
Полная запись метаданных
Поле DC | Значение | Язык |
---|---|---|
dc.contributor.author | Korenblat, Philip | en |
dc.contributor.author | Kerwin, Edwin | en |
dc.contributor.author | Leshchenko, Igor | en |
dc.contributor.author | Yen, Karl | en |
dc.contributor.author | Holweg, Cecile T.J. | en |
dc.contributor.author | Anzures-Cabrera, Judith | en |
dc.contributor.author | Martin, Carmen | en |
dc.contributor.author | Putnam, Wendy S. | en |
dc.contributor.author | Governale, Laura | en |
dc.contributor.author | Olsson, Julie | en |
dc.contributor.author | Matthew, John G. | en |
dc.date.accessioned | 2022-01-24T10:53:01Z | - |
dc.date.available | 2022-01-24T10:53:01Z | - |
dc.date.issued | 2018 | |
dc.identifier.citation | Korenblat Philip, Kerwin Edwin, Leshchenko Igor, Yen Karl, Holweg Cecile T.J., Anzures-Cabrera Judith, Martin Carmen, Putnam Wendy S., Governale Laura, Olsson Julie, Matthew John G. Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids. Respiratory Medicine. - 2018. - № 134. – pp.143-149 | en |
dc.identifier.uri | http://elib.usma.ru/handle/usma/4883 | - |
dc.description.abstract | Background: Asthma is a heterogeneous and complex disease in both its clinical course and response to treatment. IL-13 is central to Type 2 inflammation and contributes to many features of asthma. In a previous Phase 2 study, lebrikizumab, an anti-IL-13 monoclonal antibody, did not significantly improve FEV1 in mild-to-moderate asthma patients not receiving ICS therapy. This Phase 3 study was designed to further assess the efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma treated with daily short-acting β2-agonist therapy alone. Methods: Adult patients with mild-to-moderate asthma were randomised to receive lebrikizumab 125 mg subcutaneously (SC), placebo SC, or montelukast 10 mg orally for 12 weeks, with an 8-week follow-up period. The primary efficacy endpoint was absolute change in pre-bronchodilator FEV1 from baseline at Week 12. Findings: A total of 310 patients were randomised and dosed in the study. The mean absolute change in FEV1 from baseline at Week 12 was higher in the lebrikizumab-treated arm compared with placebo (150 mL versus 67 mL); however, this improvement did not achieve statistical significance (overall adjusted difference of 83 mL [95% CI:-3, 170]; p = .06). Montelukast did not improve FEV1 as compared with placebo. Lebrikizumab was generally safe and well tolerated during the study. Interpretation: Lebrikizumab did not significantly improve FEV1 in mild-to-moderate asthma patients at a dose expected to inhibit the IL-13 pathway. Inhibiting IL-13 in this patient population was not sufficient to improve lung function. These data support the findings of a previous trial of lebrikizumab in patients not receiving ICS. | en |
dc.format.mimetype | application/pdf | en |
dc.language.iso | en | en |
dc.publisher | Elsevier Ltd | ru |
dc.relation.ispartof | Respiratory Medicine | ru |
dc.rights | info:eu-repo/semantics/openAccess | en |
dc.subject | MILD | en |
dc.subject | MODERATE | en |
dc.subject | ASTHMA | en |
dc.subject | LEBRIKIZUMAB | en |
dc.title | Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids | en |
dc.type | Article | en |
dc.type | info:eu-repo/semantics/article | en |
dc.type | info:eu-repo/semantics/publishedVersion | en |
local.description.firstpage | 143 | |
local.description.lastpage | 149 | |
Располагается в коллекциях: | Публикации в журналах, альманахах |
Файлы этого ресурса:
Файл | Описание | Размер | Формат | |
---|---|---|---|---|
NP_2022_051.pdf | 439,43 kB | Adobe PDF | Просмотреть/Открыть |
Все ресурсы в архиве электронных ресурсов защищены авторским правом, все права сохранены.